Catapres is a new imidazoline compound with potent antihypertensive properties. Significant reduction in blood pressure occurs between 1 and 4 hours after oral administration, with the peak effect occurring at 2 to 4 hours and the antihypertensive effect extending for 6 to 10 hours. Blood pressure is reduced in both the supine and erect positions, although the orthostatic response is the more prominent.
the cardiac hemodynamic findings suggest that the antihypertensive effect of Catapres is related to the combination of reduction in cardiac output plus decrease in peripheral resistance. Renal blood flow and glomerular filtration rate are preserved in both the supine and erect positions following Catapres administration. Contrasting with the preservation of renal blood flow and glomerular filtration rate, however, is the marked reduction in sodium chloride excretion which follows acute administration of the drug.
The clinical utility of the drug was demonstrated in the chronic outpatient study. Although Catapres administered alone exerted only modest antihypertensive effects, a markedly enhanced antihypertensive response was achieved when the drug was combined with a potent oral diuretic, with 80% of patients so treated achieving significant blood pressure reduction in both the supine and erect positions.
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Naphazoline Sodium and chloride retention Renal blood flow Glomerular filtration DESPITE the availability of numerous antihypertensive drugs, with varying mechanisms of action, there is an undeniable need for additional drugs with broader effectiveness and fewer untoward effects. Preferably, an antihypertensive drug should (1) be universally effective, (2) lower the supine and standing blood pressures to normotensive levels, (3) be free of untoward effects, and (4) have a sustained action despite prolonged administration. Until such a drug is available, inevitably the search must continue for additional agents with clinical pharmacological characteristics more closely akin to those of the "ideal" preparation.
Early studies have indicated substantial promise for a new imidazoline compound, Catapres (ST-155). Catapres (2-[2,6-dichlorphenylamine]-2-imidazoline hydrochloride) is similar in chemical structure to naphazoline and tolazoline, two familiar vasoactive drugs. It is the purpose of this report to describe the cardiorenal hemodynamic effects and clinical application of Catapres in hypertensive patients.
Methods

Cardiorenal Hemodynamic Effects
Studies were performed on seven human volunteers who had essential hypertension. The patients were hospitalized and placed on a 5-g salt diet. No antihypertensive drugs were administered for at least 2 weeks prior to the investigation. The hemodynamic studies were performed in the fasting state except for hydration with 500 ml of tap water given 1 hour prior to the procedure.
Cardiac outputs were determined by the indicator-dilution technique, using indocyanine green and a Gilford densitometer. Intra-arterial blood pressures were recorded from the brachial artery with a Statham strain-gauge transducer. Pulse pressures and dye curves were recorded on a photographic oscillograph. Renal plasma flow was measured by para-aminohippurate clearance and glomerular filtration rate by inulin clearance. Total peripheral resistance was calculated from the mean arterial pressure (obtained by electronic integration) and cardiac output. Renal vascular resistance was calculated from the mean arterial blood pressure and the renal blood flow according to the Gomez formula.I After the subjects had rested for 45 minutes in the supine position on a standard tilt table, control cardiac and renal hemodynamic studies were performed. The cardiac and renal studies were synchronized, with the cardiac outputs being performed during the middle of each clearance period. The studies were done in duplicate in the supine position. Subsequently the patient was tilted 45 0 upright and after a 15-minute equilibration time, the cardiac and renal studies were repeated in duplicate in the tilted position. Following the control determinations, Catapres was administered orally in an initial dose of 0.3 mg; an additional dose was given 1 hour later resulting in a total dose of 0.45 to 0.75 mg.
Blood pressures were recorded in the 450-tilt position until a satisfactory drop in blood pressure was noted. The patient was then passively returned to the supine position. After a 15minute equilibration time, cardiac and renal function studies were performed in duplicate. The patient was then tilted passively 450 upright and after another 15-minute equilibration time, the cardiac and renal studies were repeated in duplicate. The reported results in each case represent the average of two determinations.
Clinical Studies
The antihypertensive effect of Catapres given orally was studied in two groups of ambulatory patients with essential hypertension. The first group was treated with Catapres alone, while the second received Catapres plus chlorthalidone. The patients were selected randomly from the Hypertension Clinic.
The first group consisted of 16 patients with blood pressures greater than 150/100 mm Hg. The patients were given daily placebo medication for a minimum period of at least 4 weeks. The patients returned to the clinic at weekly or biweekly intervals, at which time the blood pressure and physical signs and symptoms were recorded. After the control period, administration with Catapres was begun in an initial dosage of 0.075 mg daily. Thereafter, the dosage was increased at biweekly intervals to a maximum of 0.9 mg daily (0.3 mg t.i.d.). Treatment with Catapres alone was continued for 12 to 28 weeks.
The second group consisted of 34 patients with blood pressures greater than 150/100 mm Hg. The patients were given daily placebo medication for a minimum period of at least 4 weeks. They returned at biweekly intervals at which time blood pressure and physical signs and symptoms were recorded. After the control period the 34 patients were treated with chlorthalidone (Hygroton) alone, in a dosage of 100 mg daily, for a minimum of 28 days. After treatment with chlorthalidone, 20 of the 34 patients continued to have blood pressures consistently greater than 150/100 mm Hg. These 20 patients continued to receive chlorthalidone (100 mg daily) and, in addition, Catapres was added to the therapeutic regimen. The initial dosage of Catapres ranged from 0.075 to 0.15 mg daily for all patients except one who received an initial daily dose of 0.6 mg. Thereafter the dosage of Catapres was increased until a satisfactory reduction in blood pressure was achieved or until further increase in dosage was precluded because of side effects. The 20 patients were continued on combined therapy with chlorthalidone and Catapres for periods ranging from 140 days to 250 days. The maximum dosage of Catapres employed was 0.9 mg per day.
Results
Cardiorenal Hemodynamic Effects
The onset of antihypertensive effect was noted as early as 30 minutes following oral administration of Catapres. Significant blood pressure reduction occurred between 1 and 4 hours after oral administration, with peak effect at 2 to 4 hours. The antihypertensive effect lasted 6 to 10 hours.
The hemodynamic effects of Catapres in the supine position are recorded in table 1. Significant reduction of blood pressure was observed in six of the seven patients studied. The average mean arterial blood pressure reduction was 17% (P <0.01). The cardiac output was reduced in every patient, with an average reduction of 21% (P <0.01). Reduction of heart rate also occurred in each case, with an average fall of 10% (P <0.01). Mild Qr <r > t cn~~~~~~~~x cTt x w: 
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There was no consistent change in total peripheral resistance. Similarly, there was no significant alteration in renal blood flow or glomerular filtration rate. The hemodynamic effects of Catapres in the 450 tilt are recorded in table 2. A significant reduction in blood pressure occurred in each patient studied. The average mean blood pressure reduction was 33% (P < 0.001). The cardiac output was reduced in six patients and unchanged in one; the average decrease in cardiac output was 15% (P < 0.05). The heart rate decreased in five patients but was essentially unchanged in two. The average drop in heart rate was 14% (P <0.05). There were no consistent changes in stroke volume. In contrast to the response in the supine position, there was a consistent and significant reduction in total peripheral resistance, with an average decrease of 21% (P <0.02). Despite the substantial blood pressure reduction in the erect position, there was no consistent change in renal blood flow or glomerular filtration rate. On the other hand, there was a substantial and significant decrease in renal vascular resistance, with an average reduction of 30% (P < 0.01).
The electrolyte excretion responses to Catapres, in the supine and erect positions, are shown in tables 1 and 2, respectively. Sodium and chloride excretion dropped markedly in each case, while excretion of potassium did not show any consistent change.
The changes induced by 450 head-up tilting in the control period are shown in table 3 and after Catapres in table 4. In the control studies, passive 45°head-up tilting failed to produce any significant effect on arterial pressure; however, a 24% decrease in cardiac output, 28% decrease in stroke volume, 27% increase in total peripheral resistance, 16% reduction in renal blood flow, and 15% decrease in glomerular filtration rate occurred. During the antihypertensive response to Catapres, the tilting maneuver again resulted in a fall in cardiac output and stroke volume; however, in contrast to the control studies, significant increases in total peripheral resistance did not occur ( fig. 1 ). Although renal blood flow and glomerular filtration rate decreased with head-up tilting during the antihypertensive response to Catapres, it is noteworthy that the decrease was of similar magnitude to that of the control response, despite the greater orthostatic blood pressure reduction following drug administration ( fig. 2 Cardiac hemodynamic effects of passive head-up tilting (450), control (above) and after Catapres (below). After Catapres administration, there was no significant change in total peripheral resistance, despite reduction in cardiac output. Renal hemodynamic effects of passive head-up tilting (450), control (above) and after Catapres (below). Despite greater orthostatic blood pressure reduction after Catapres administration, renal vascular resistance decreased and renal hemodynamic functions were of the same magnitude as those observed in the control studies. Abbreviations: M = male; F = female; N = Negro.
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Clinical Studies
The blood pressure response of the 16 patients treated with Catapres alone is tabulated in table 5. Of the 16 patients in this group, three obtained a significant blood pressure reduction* in the supine position, and one of the 16 became normotensive. When blood pressure was measured in the upright position, six patients obtained a significant antihypertensive response. There was no evidence of tolerance to Catapres alone. Side effects encountered with Catapres alone included: drowsiness (11 patients), dryness of mouth (five patients), constipation (one patient), and orthostatic weakness (one patient). The drowsiness improved in three patients and cleared entirely in two others. In the remaining patients, the drowsiness ranged from mild to moderate severity.
The blood pressure response of the pa-*The achievement of normotension (140/90 mm Hg) or a reduction in mean arterial blood pressure of 20 mm Hg or more was considered significant. tients treated with Catapres plus chlorthalidone is tabulated in table 6. Of the 20 patients in this group, 16 obtained a significant blood pressure reduction in the supine position, and one of the 16 became normotensive. Similarly, when blood pressures were measured in the erect position, 16 patients obtained a significant antihypertensive response, while two of the 16 became normotensive. Among the group, the most frequent side effect was drowsiness which was experienced by 10 of the 20 patients. Although moderate tolerance for drowsiness was acquired by those affected, the drowsiness persisted during the entire period of treatment. Other side effects included dry mouth (six patients), dizziness (six patients), constipation (five patients), and nausea (one patient).
Discussion
Catapres shares a marked similarity in chemical structure with the two familiar vasoactive compounds, tolazoline and naphazoline ( fig. 3 ). Tolazoline is classified pharmacologically as an alpha-adrenergic block- [ Figure 3 Chemical structures of Catapres, naphazoline, and tolazoline.
ing agent. However, despite the fact that tolazoline when administered alone will lower the blood pressure in erect man, this drug has been shown to reverse promptly and completely the hypotensive effect of Catapres and, in fact, has been considered the pharmacological antidote for Catapres.2 Naphazoline, on the other hand, is known for its vasoconstrictor and pressor effects and is considered to be a potent adrenergic substance. Whereas Catapres has vasodepressor effects, it shares with naphazoline the property of a nasal decongestant. Thus Catapres, with like chemical structure but varying pharmacological similarities and dissimilarities to tolazoline and naphazoline, probably shares common sympathetic receptor sites while substituting or sharing pharmacological mechanisms of action.
It is noteworthy that Catapres shares many pharmacological similarities with reserpine, that is, both agents induce reduction of blood pressure, bradyeardia, and sedation. However there are numerous dissimilarities also. Reserpine causes swelling of the nasal mucous membranes, stimulates gastric secretion and intestinal motility, and is associated with lowering of catecholamine levels in the heart, arterioles, and brain. Contrariwise, Catapres causes nasal decongestion, decreases gastric secretion and intestinal motility, and is unassociated with significant catecholamine alterations in the tissues. Thus, the fundamental mechanism whereby Catapres exerts its antihypertensive effect is currently unknown. 3 The cardiac hemodynamic studies demonstrate that in the supine position, the blood TOLAZOLINE (Priscoline)
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CH2-C\ NIOH pressure lowering effect of Catapres is related to a reduction in cardiac output while there is no significant effect on peripheral vascular resistance. The decrease in cardiac output appears to be secondary to reduction in both heart rate and stroke volume. In contrast, in the erect position the peripheral vascular resistance is lowered significantly (by 21% as compared with control values). Although the cardiac output is also lowered in the erect position, the reduction is actually somewhat less than that observed in the supine posture. The relative preservation of cardiac output in the erect position appears to be related to the maintenance of stroke volume and a less pronounced reduction in the heart rate.
The drug-induced reduction of cardiac output may be due to decreased venous return to the right heart or to a direct myocardial effect, or both. In this regard, it is noteworthy that animal studies have failed to show any change in myocardial contractility. In contrast, animal studies have shown an increase in the total capacity of the circulation, probably resulting from systemic venodilatation.4 The bradycrotic effect of the drug is noteworthy since it reflects a loss of the usual reflex-induced increase in heart rate which ordinarily follows blood pressure reduction or assumption of the erect posture. Animal studies suggest that this effect may be due to direct inhibition of the sino-atrial node. 4 Although peripheral vascular resistance does not change significantly in the supine position following administration of Catapres, Circulation, Volume XXXIX, February 1969 this finding is notable in itself in that peripheral resistance would be expected to rise in response to the drug-induced reduction in cardiac output. Thus an effect on peripheral resistance is manifest even with the patient supine. Accordingly, the cardiac hemodynamic findings in toto suggest that the antihypertensive effect of Catapres is related to the combination of reduction in cardiac output plus decrease in peripheral vascular resistance, with the latter effect predominating in the erect position.
Renal hemodynamic functions (renal blood flow and glomerular filtration rate) are preserved in both the supine and erect positions following administration of Catapres. This is an extremely favorable pharmacodynamic effect, especially in view of the fact that a decrease in renal blood flow and glomerular filtration rate ordinarily follows acute blood pressure reduction. Methyldopa and hydralazine are the only two currently available antihypertensive drugs which share this favorable renal hemodynamic effect.5 ' 6 Contrasting sharply with the preservation of renal blood flow and glomerular filtration rate is the marked sodium and chloride retention which occurs acutely after Catapres administration. The modest drug-induced re-duction in cardiac output was not of sufficient magnitude to account for the sharp reduction in excretion of sodium chloride. Thus, although the decrease in sodium and chloride excretion cannot be explained clearly from this investigation, the findings suggest the possibility of a direct effect of the drug on tubular reabsorption of sodium and chloride. Davidov and co-workers7 have also noted the sodium retentive effects of the drug.
In view of the marked inhibition of sodium and chloride excretion, it would be anticipated that augmentation of the antihypertensive effect would be gained by the simultaneous administration of a diuretic along with Catapres. This premise was substantiated by the findings of the outpatient study. Catapres administered alone exerted only modest antihypertensive effects. However, when chlorthalidone was administered in combination with Catapres, a potentiated antihypertensive effect was obtained, with 80% of the patients achieving significant blood pressure reduction. Particularly noteworthy is the finding that combination drug therapy produced similarly favorable blood pressure reductions in both the supine and the erect positions. The findings in this regard are somewhat more favorable than those obtained Table 7 Comparative Antihypertensive Effects of Guanethidine, Pargyline,a ca-MAlethyldopa and Catapres, Abbreviations: Normotensive = blood pressure reduced to 140/90 mm Hg or less; responsive = mean blood pressure reduced >20 mm Hg or normotensive.
Circulation, Volume XXXIX, February 1969 a la Proust Man responds not as a mechanical assemblage of parts, but as an integrated organism with a complex history. Any physicochemical or psychic stimulus which impinges on him sets in motion a host of secondary processes with very indirect and often delayed effects. Seeing an object which recalls an article of food may stimulate appetite or cause nausea; smelling an artificial perfume may evoke the heat of a summer day, or the chill of a fall evening; hearing a faint but unexpected noise at night may cause either a rise or fall in blood pressure. In other words, the ultimate physiological or mental expression of stimuli commonly has little bearing on their primary direct effects.-RENE DUBOS: Hippocrates in Modern Dress. Proc Inst Med Chicago 25: 247, 1964-65.
